TAILOR BIO
LIVE

Serial Number

98549945

Owner

TAILOR BIO LTD

Attorney

Richard S. Finkelstein

Filing Date

May 14, 2024

Add to watchlist:

No watchlists yet
View on USPTO

TAILOR BIO Trademark

Serial Number: 98549945 • Registration: 7806673

TAILOR BIO is a trademark filed by TAILOR BIO LTD on May 14, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

TAILOR BIO LTD

Main Road, Barleythorp
Oakham, Rutland LE157WD , GB

Entity Type: 99

Trademark Details

Filing Date

May 14, 2024

Registration Date

May 27, 2025

Published for Opposition

April 8, 2025

Goods & Services

Publication of books; Publication of journals; Publication of electronic books and journals online; Publication of material, namely, teaching materials that can be accessed from databases or from the Internet; Publication of scientific research findings; Publication of electronic books and journals featuring the results of clinical trials; Publication of electronic books and journals featuring the results of clinical trials for pharmaceutical preparations

Downloadable software for data analysis of the genome for chromosomal instabilities; Downloadable application software for data analysis of the genome for chromosomal instabilities; Downloadable computer software for data analysis of the genome for chromosomal instabilities; Downloadable bioinformatics software for data analysis of the genome for chromosomal instabilities; Downloadable computer software platforms for data analysis of the genome for chromosomal instabilities; Downloadable artificial intelligence software for data analysis of the genome for chromosomal instabilities; Downloadable artificial intelligence software platforms for data analysis of the genome for chromosomal instabilities; Downloadable artificial intelligence software for searching, tracking, exploration, and analysis of data for use in the field of healthcare; Downloadable artificial intelligence software for searching, tracking, exploration and analysis of data for use in the research and development of pharmaceutical preparations and medicines for cancers with chromosomal abnormalities; Computer hardware and downloadable software for use with medical patient monitoring equipment, for receiving, processing, transmitting and displaying data; Scientific apparatus and instruments, namely, spectrometers, centrifuges, and microscopes for use in laboratory research; Scientific specimens for laboratory use, namely, prepared microscope slides and sample vials containing chemical reagents

Pharmaceuticals, namely, for the treatment of cancers; Pharmaceutical drugs, namely, for the treatment of cancers; Pharmaceutical preparations for the treatment of cancers; Pharmaceutical preparations for the treatment of cancers with chromosomal abnormalities; Pharmaceutical preparations for the treatment of cancers with chromosomal instabilities; Pharmaceutical preparations acting on cancers; Pharmaceutical preparations acting on cancers with chromosomal abnormalities; Pharmaceutical preparations acting on cancers with chromosomal instabilities; Medicine, namely, for the treatment of cancers; Medicines for human purposes, namely, for the treatment of cancers; Medicine for the treatment of cancers with chromosomal abnormalities; Medicine for the treatment of cancers with chromosomal instabilities; Chemicals for pharmaceutical use, namely, for the treatment of cancers; Chemical reagents for medical use; Chemical preparations for medical purposes, namely, for the treatment of cancers; Drugs for medical purposes, namely, for the treatment of cancers, Diagnostic reagents and preparations for medical or veterinary use, Kits containing chemical reagents and a protocol for use thereof for medical purposes

Database management; Database management and reporting services for business purposes; Business information services; Business consulting services; Business consulting services in the field of drug discovery; Business consulting services in the field of biomarker discovery; Business consulting services in the field of genomics; Business consulting in the field of chromosomal abnormalities; Market intelligence services; Data processing; Data processing in the field of drug discovery; Data processing in the field of medical diagnosis; Data processing in the field of biomarker discovery; Data processing in the field of genomics; Data processing in the field of bioinformatics; Data processing in the field of chromosomal abnormalities; Data processing in the field of chromosomal instabilities; Information, advisory and consultancy services in relation to all of the aforesaid

Agents, reagents, assays, enzymes, nucleotides, buffers, chemical preparations, and biological preparations for scientific and research use; Diagnostic reagents and preparations, except for medical or veterinary use; Kits containing chemical reagents and a protocol for use thereof for non-medical purposes; Agents, reagents, assays, enzymes, nucleotides, buffers, chemical preparations, and biological preparations for scientific and research use in the fields of nucleic acid sequencing, genotyping, diagnostics, diagnostic research, clinical research, drug development, pharmaceuticals, laboratory research, scientific research, medical research, life sciences, biology, microbiology and metagenomics, biotechnology, agriculture, forensics, food safety, genetic testing, and genetics; Kits comprising nucleotides, reagents, enzyme substrates, buffers, chemical preparations, or biological preparations for scientific and research use including in the fields of nucleic acid sequencing, genotyping, diagnostics, diagnostic research, clinical research, drug development, pharmaceuticals, laboratory research, scientific research, medical research, life sciences, biology, microbiology and metagenomics, and biotechnology.

Healthcare services; Healthcare information, advisory and consultancy services for cancers with chromosomal abnormalities; Healthcare information, advisory and consultancy services for cancers with chromosomal instabilities; Medical services; Medical information, advisory and consultancy services for cancers with chromosomal abnormalities; Medical testing for diagnostic or treatment purposes; Pharmaceutical services, namely, pharmaceutical compounding services; Pharmaceutical information relating to diagnostic properties of pharmaceuticals; Pharmaceutical advisory and consultancy services for cancers with chromosomal abnormalities; Pharmaceutical services, namely, pharmaceutical advice; Pharmaceutical information relating to, advisory and consultancy services for cancers with chromosomal instabilities; Advisory and collation of medical information in the healthcare sector in the field of pharmaceuticals; Providing medical information in the healthcare sector; Providing medical information concerning pharmaceuticals and the research and development of pharmaceuticals for cancers with chromosomal abnormalities; Advisory and collation of information in the healthcare sector; Providing medical information concerning pharmaceuticals and the research and development of pharmaceuticals for cancers with chromosomal instabilities; Health consultancy; Medical treatment services; Provision of personalised medicine information in the field of rare diseases; Medical advisory services relating to rare diseases; Advisory services relating to treatment of rare diseases; Medical health assessment services; Advisory services relating to medical instruments, namely, providing guidance on the selection and use of medical diagnostic instruments for healthcare professionals; Therapy services, namely, gene therapy services; Medical and health care services relating to DNA, genetics and genetic testing; Genetic testing for medical purposes; Providing cancers screening services

Compilation of data for use in scientific research; Data analysis in the field of genomics; Data analysis in the field of biomarker discovery; Scientific and technological services, namely, research in the fields of bioinformatics and drug discovery; Design and development of computer software; Providing online non-downloadable computer software for analyzing genomic and healthcare data; Platform as a Service [PaaS] featuring computer software platforms for data exploration and analysis in the field of healthcare; Platform as a Service [PaaS] featuring computer software platforms for data analysis in the research and development of pharmaceutical preparations; Software as a Service [SaaS] featuring computer software for data exploration in the field of healthcare; Software as a Service [SaaS] featuring artificial intelligence computer software for analyzing chromosomal abnormalities and instabilities; Medical and scientific research in the field of drug target discovery for development of pan-cancer precision therapies; Genetic engineering services, namely, scientific research in the field of genetic engineering; Scientific research in the field of genetics and drug discovery; Scientific research conducted using databases and the Internet in the field of genetics; Pharmaceutical research and development services; Drug discovery services; Scientific research and development; Consulting services in the fields of pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 27, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
May 27, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 8, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 8, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 2, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 13, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 13, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 13, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 13, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 13, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 24, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 24, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 9, 2024 GNRN
NON-FINAL ACTION E-MAILED
Dec 9, 2024 GNRT
NON-FINAL ACTION WRITTEN
Dec 9, 2024 CNRT
ASSIGNED TO EXAMINER
Nov 27, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 14, 2024 NWOS
NEW APPLICATION ENTERED
May 14, 2024 NWAP